Mitsubishi Tanabe Obtains Right To Kidney Drug From Canadian Cytochroma
This article was originally published in PharmAsia News
Executive Summary
Mitsubishi Tanabe Pharmaceutical announced July 30 it signed a licensing agreement and obtained exclusive rights to develop and market CTA018 in the U.S. and Asia including Japan with Cytochroma, a Canadian bio-venture company. CTA018 is a vitamin D analog used to treat secondary hyperparathyroidis in patients with chronic kidney disease, and is entering Phase II development in Canada. According to the company, CTA018 is more effective in lowering parathormone compared to the current vitamin D analog. Cytochroma could receive up to CDN$105 million in up-front payments, milestone payments and an equity investment. (Click here for more - Japanese language
You may also be interested in...
Mitsubishi Tanabe’s Domestic Remicade Sales Jump 41.2 Percent, Result In Better Performance
TOKYO - Stable Japanese sales of Mitsubishi Tanabe's rheumatoid arthritis drug Remicade (infliximab) translated to better performance for the April to June quarter, the company reported July 30
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.